Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$957.76+5.36 (+0.56%)
Close on Nov 17, 2026Market cap $99.08BP/E 21.2Yield –
Regeneron Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Regeneron Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was $4.86B, up 31.9% year over year. For fiscal 2025 it was $3.58B, down 10.3% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is $8.95B in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.58B | -10.3% |
| FY2024 | Dec 31, 2024 | $3.99B | -1.4% |
| FY2023 | Dec 31, 2023 | $4.05B | -14.6% |
| FY2022 | Dec 31, 2022 | $4.74B | -47.0% |
| FY2021 | Dec 31, 2021 | $8.95B | +150.1% |
| FY2020 | Dec 31, 2020 | $3.58B | +61.9% |
| FY2019 | Dec 31, 2019 | $2.21B | -12.8% |
| FY2018 | Dec 31, 2018 | $2.53B | +21.9% |
| FY2017 | Dec 31, 2017 | $2.08B | +56.3% |
| FY2016 | Dec 31, 2016 | $1.33B | +6.3% |
| FY2015 | Dec 31, 2015 | $1.25B | +51.9% |
| FY2014 | Dec 31, 2014 | $823.92M | +10.9% |
| FY2013 | Dec 31, 2013 | $743.05M | +62.3% |
| FY2012 | Dec 31, 2012 | $457.71M | – |
| FY2011 | Dec 31, 2011 | -$205.16M | – |
| FY2010 | Dec 31, 2010 | -$97.47M | – |
| FY2009 | Dec 31, 2009 | -$74.10M | – |
| FY2008 | Dec 31, 2008 | -$86.25M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.05B | +99.5% |
| Q2 FY2026 | Jun 30, 2026 | $1.29B | +19.8% |
| Q1 FY2026 | Mar 31, 2026 | $642.90M | +8.7% |
| Q4 FY2025 | Dec 31, 2025 | $879.90M | -11.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.03B | -12.9% |
| Q2 FY2025 | Jun 30, 2025 | $1.08B | +0.9% |
| Q1 FY2025 | Mar 31, 2025 | $591.70M | -21.3% |
| Q4 FY2024 | Dec 31, 2024 | $990.20M | +1.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.18B | +6.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.07B | +5.2% |
| Q1 FY2024 | Mar 31, 2024 | $751.40M | -20.6% |
| Q4 FY2023 | Dec 31, 2023 | $972.90M | -15.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.11B | -9.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.02B | -8.4% |
| Q1 FY2023 | Mar 31, 2023 | $946.70M | -24.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.15B | -56.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.22B | -33.8% |
| Q2 FY2022 | Jun 30, 2022 | $1.11B | -66.8% |
| Q1 FY2022 | Mar 31, 2022 | $1.26B | +13.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.64B | +126.2% |
| Q3 FY2021 | Sep 30, 2021 | $1.85B | +75.4% |
| Q2 FY2021 | Jun 30, 2021 | $3.35B | +409.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.11B | +58.9% |
| Q4 FY2020 | Dec 31, 2020 | $1.17B | +72.7% |
| Q3 FY2020 | Sep 30, 2020 | $1.05B | +42.6% |
| Q2 FY2020 | Jun 30, 2020 | $656.40M | +108.0% |
| Q1 FY2020 | Mar 31, 2020 | $700.10M | +45.9% |
| Q4 FY2019 | Dec 31, 2019 | $675.70M | -5.9% |
| Q3 FY2019 | Sep 30, 2019 | $738.50M | +17.8% |
| Q2 FY2019 | Jun 30, 2019 | $315.60M | -49.3% |
| Q1 FY2019 | Mar 31, 2019 | $480.00M | -15.4% |
| Q4 FY2018 | Dec 31, 2018 | $718.10M | +33.3% |
| Q3 FY2018 | Sep 30, 2018 | $626.90M | +12.0% |
| Q2 FY2018 | Jun 30, 2018 | $622.20M | +13.1% |
| Q1 FY2018 | Mar 31, 2018 | $567.20M | +31.7% |
| Q4 FY2017 | Dec 31, 2017 | $538.82M | +55.3% |
| Q3 FY2017 | Sep 30, 2017 | $559.93M | – |
| Q2 FY2017 | Jun 30, 2017 | $550.31M | – |
| Q1 FY2017 | Mar 31, 2017 | $430.54M | – |
| Q4 FY2016 | Dec 31, 2016 | $346.96M | – |
See a number that looks wrong?